ProVen Growth and Income VCT plc: Total voting rights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailProVen Growth and Income VCT plc
Total Voting Rights
28 March 2024
In conformity with the Disclosure and Transparency Rule 5.6.1, ProVen Growth and Income VCT plc (the “Company”) announces that the Company's capital and voting rights, as at 28 March 2024, are summarised as follows:
| Shares in issue | Voting rights per Share | Voting rights | |
| Ordinary shares of 1.6187p each | 307,112,893 | 1 | 307,112,893 |
| Total voting rights | 307,112,893 | ||
The Company does not hold any shares in treasury.
The above takes account of any shares that have been recently bought back for cancellation, even if such transactions have not yet settled.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, ProVen Growth and Income VCT plc under the FCA's Disclosure and Transparency Rules.
Beringea LLP
Company Secretary
Telephone 020 7845 7820
- End
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pacera launches Pacera Lease by AARO in the UK, bringing more than 30 years of AARO accounting heritage to FRS 102 lease reporting.
- TRG Screen brings terminal usage into focus with Activity Monitor
- Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
